Multiple myeloma diagnostic criteria: Difference between revisions
Hannan Javed (talk | contribs) |
Hannan Javed (talk | contribs) |
||
| Line 45: | Line 45: | ||
===Criteria for the Diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS)=== | ===Criteria for the Diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS)=== | ||
All three criteria must be met: | All three criteria must be met: | ||
* Presence of serum monoclonal protein (IgG or IgA) <3 g/dL | * Presence of serum monoclonal [[protein]] ([[IgG]] or [[IgA]]) <3 g/dL | ||
* Presence of bone marrow clonal plasma cells <10% | * Presence of [[bone marrow]] clonal [[plasma cells]] <10% | ||
* Absence of multiple myeloma-defining events or amyloidosis | * Absence of [[multiple myeloma]]-defining events or [[amyloidosis]] | ||
===Criteria for the Diagnosis of Smoldering Multiple Myeloma=== | ===Criteria for the Diagnosis of Smoldering Multiple Myeloma=== | ||
Both criteria must be met<ref name="lancet">Rajkumar, S. Vincent, Meletios A. Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar et al. "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma." The Lancet Oncology 15, no. 12 (2014): e538-e548</ref>: | Both criteria must be met<ref name="lancet">Rajkumar, S. Vincent, Meletios A. Dimopoulos, Antonio Palumbo, Joan Blade, Giampaolo Merlini, María-Victoria Mateos, Shaji Kumar et al. "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma." The Lancet Oncology 15, no. 12 (2014): e538-e548</ref>: | ||
* Serum monoclonal protein (IgG or IgA) ≥3 g/dL or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60% | * Serum monoclonal [[protein]] ([[IgG]] or [[IgA]]) ≥3 g/dL or [[urinary]] monoclonal [[protein]] ≥500 mg per 24 h and/or clonal [[bone marrow]] [[plasma cells]] 10–60% | ||
* Absence of multiple myeloma-defining events or amyloidosis | * Absence of [[multiple myeloma]]-defining events or [[amyloidosis]] | ||
==References== | ==References== | ||
| Line 58: | Line 58: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
;[[Category:Disease]] | ;[[Category:Disease]] [[Category:Hematology]] [[Category:Types of cancer]] [[Category:Up-To-Date]] [[Category:Oncology]] [[Category:Medicine]] [[Category:Neurology]] [[Category:Neurosurgery]] | ||
Revision as of 15:02, 7 November 2018
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma diagnostic criteria On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma diagnostic criteria |
|
Risk calculators and risk factors for Multiple myeloma diagnostic criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2] Associate Editor(s)-in-Chief: Serge Korjian M.D. Shyam Patel [3]
Overview
The diagnosis of monoclonal gammopathy of undetermined significance requires the presence of clonal plasma cells < 10% and serum monoclonal protein <3g/dl but the absence of end-organ damage. The diagnosis of smoldering multiple myeloma requires the presence of clonal plasma cells 10%-60% and serum monoclonal protein >3g/dl but the absence of end-organ damage. The diagnosis of active multiple myeloma requires the presence of end-organ damage. In November 2014, the International Myeloma Working Group (IMWG) updated the criteria for the diagnosis of multiple myeloma to include novel validated biomarkers to better encompass the extent of disease. Prior to 2014, the original diagnostic criteria for end-organ damage included CRAB features (hypercalcemia, renal failure, anemia, and bone lesions) without consideration of the plasma cell burden or free light chain ratio. The 2014 update also clarified the underlying laboratory and radiographic findings of CRAB features, as well as the histological and monoclonal protein requirements for the disease diagnosis.[1]
Diagnostic Criteria
Revised Criteria for the Diagnosis of Multiple Myeloma
The diagnosis of multiple myeloma requires the following:[1]
- ≥10% clonal plasma cells in bone marrow
OR
- biopsy-proven bony or extramedullary plasmacytoma,
With one or more of the CRAB features and myeloma-defining events:
- CRAB features:
- Hypercalcemia: serum calcium >0·25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2·75 mmol/L (>11 mg/dL)
- Renal insufficiency: creatinine clearance <40 mL per min or serum creatinine >177 μmol/L (>2 mg/dL)
- Anemia: hemoglobin value of >2 g/dL below the lower limit of normal, or a hemoglobin value <10 g/dL
- Bone lesion: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
- Myeloma-defining events:
- Bone marrow plasma cell burden: Clonal bone marrow plasma cell percentage ≥60%
- Free light chain ratio: Involved-to-uninvolved free light chain ratio ≥100
- MRI: >1 focal bony lesion of 5mm or greater on MRI studies
| Revised Criteria for the Diagnosis of Multiple Myeloma |
|---|
OR
With one or more of the following:
|
Criteria for the Diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS)
All three criteria must be met:
- Presence of serum monoclonal protein (IgG or IgA) <3 g/dL
- Presence of bone marrow clonal plasma cells <10%
- Absence of multiple myeloma-defining events or amyloidosis
Criteria for the Diagnosis of Smoldering Multiple Myeloma
Both criteria must be met[1]:
- Serum monoclonal protein (IgG or IgA) ≥3 g/dL or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60%
- Absence of multiple myeloma-defining events or amyloidosis